Why the study?
The prevalence and functional relevance of CHIP in CAD were unclear, and CHIP-affected cells had not been detected in human atherosclerotic plaques.
Population
540 deceased CAD patients from MISSION and 941 patients from STARNET
Comparison
CHIP mutation carriers vs non-carriers
Design
Observational sequencing and tissue analysis study
Key result
CHIP mutations were highly prevalent in patients with coronary artery disease (46.9% in the MISSION cohort and 14.2% in the STARNET cohort), with CHIP-mutated leukocytes directly invading human atherosclerotic plaques.
Authors
Loading...
CHIP-mutated cells in plaques may implicate CHIP in CAD progression; leaves open causal contribution and need for targeted trials.
Observational (n=1,481)
Yes
This study provides direct evidence that CHIP-mutated leukocytes invade human atherosclerotic plaques and exhibit distinct, mutation-specific pro-atherosclerotic signaling profiles.
Scheidt et al. (2023) conducted an observational in Coronary artery disease (n=1,481). Clonal Hematopoiesis of Indeterminate Potential (CHIP) mutations vs. Non-carriers was evaluated on Prevalence of CHIP mutations in whole blood. CHIP mutations were highly prevalent in patients with coronary artery disease (46.9% in the MISSION cohort and 14.2% in the STARNET cohort), with CHIP-mutated leukocytes directly invading human atherosclerotic plaques.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: